Threshold Pharmaceuticals (THLD) 3.81 $THLD
Threshold Pharmaceuticals Announces Presentation and Webcast at the UBS Global Healthcare Conference
Marketwire - 45 mins ago
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the UBS Global Healthcare Conference on May 20, 2014, at 12:30 p.m. ET.
Threshold CEO Named as Finalist for European Inventor Award
Marketwire - Wed May 07, 5:07AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Harold E. "Barry" Selick, Ph.D., Chief Executive Officer of Threshold and Cary L. Queen, Ph.D., President of Galaxy Biotech, have been jointly named as finalists for the European Inventor Award 2014 in the "Non-European Countries" category. Their nomination is in recognition of their work while at Protein Design Labs, Inc. ("PDL"
in inventing the humanized monoclonal antibody technology that is embodied in numerous therapeutics such as Avastin(R) and Herceptin(R), as well as Zenapax(R), which was the first humanized antibody therapeutic that was approved as a drug by the U.S. Food & Drug Administration (FDA) and which was PDL's first product. Dr. Queen, who led the antibody humanization program, was the co-founder and head of research at PDL while Dr. Selick was a staff scientist working with him at the time. The final award ceremony at which the winners in each of 5 different categories will be announced will take place in Berlin, Germany, on June 17, 2014.
Threshold Pharmaceuticals Reports First Quarter 2014 Financial and Operational Results
Marketwire - Thu May 01, 6:01AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the first quarter 2014. Revenue for the first quarter ended March 31, 2014 was $3.7 million. The operating loss for the first quarter ended March 31, 2014 was $8.6 million. The net loss for the first quarter ended March 31, 2014 was $7.1 million, which included the operating loss of $8.6 million and non-cash income of $1.5 million related to the changes in fair value of the Company's outstanding and exercised warrants and was classified as other income (expense). As of March 31, 2014, Threshold had $86.4 million in cash, cash equivalents and marketable securities, with no debt outstanding.
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany Initiates Phase 1 Dose Escalation Study of TH-302 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane(R)) in Pancreatic Cancer
Marketwire - Thu Mar 27, 6:00AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has initiated a Phase 1 dose escalation study assessing the safety, tolerability and anti-tumor activity of the investigational hypoxia-targeted drug TH-302 in combination with gemcitabine and nab-paclitaxel (Abraxane(R)) in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Investors look to Lighten Up on Shares of Threshold Pharmaceuticals, Shares Down 9.4% (THLD)
Comtex SmarTrend(R) - Mon Mar 24, 10:42AM CDT
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 9.4% to $4.51 on 1.3x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 691,000 shares, vs. average volume of 526,000 shares per day. The stock has underperformed the Dow (-9.4% to the Dow's -0.3%) and underperformed the S&P 500 (-9.4% to the S&P's -0.7%) during today's trading.
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
Marketwire - Thu Mar 06, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, the Company's investigational hypoxia-targeted drug, which is currently being evaluated in two pivotal Phase 3 clinical trials, one in patients with advanced soft tissue sarcoma and the other in patients with advanced pancreatic cancer. Revenue for the fourth quarter and year ended December 31, 2013 was $3.2 million and $12.5 million, respectively. Net loss for the fourth quarter ended December 31, 2013 was $7.6 million, which included the operating loss of $7.8 million and non-cash income of $0.2 million related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense). Net loss for the year ended December 31, 2013 was $28.4 million, which included the operating loss of $26.0 million and non-cash expense of $2.3 million related to changes in the fair value of the Company's outstanding and exercised warrants. As of December 31, 2013, Threshold had $82.0 million in cash, cash equivalents and marketable securities, with no debt outstanding. Subsequent to December 31, 2013, Threshold received a $12.5 million milestone payment, which was earned during the fourth quarter of 2013, under its global license and co-development agreement with Merck KGaA, Darmstadt, Germany. The agreement includes an option for Threshold to co-commercialize TH-302 in the U.S.
5 States Where Pancreatic Cancer Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 11:15AM CST
There is no making light of the fact that cancer is a terrible disease, claiming more lives in the U.S. each year save for heart disease. What's even scarier is that cancer prevalence is rising in the U.S., whereas a number of other leading causes of...
3 Biotech Companies That Could Be the Next Intercept or InterMune
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 2:43PM CST
Nearly every industry has witnessed a huge rebound since the market bottomed out in March 2009, but few have delivered as strong a gain since 2012 as the biotech sector. Simply put, biotech stocks are on fire. Venture capital is pouring into the...
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences
Marketwire - Thu Feb 20, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences:
Stock to Watch: Threshold Pharmaceuticals Down 6.4% (THLD)
Comtex SmarTrend(R) - Mon Feb 03, 12:46PM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 6.4% to $4.57 on 1.4x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 828,000 shares, vs. average volume of 587,000 shares per day. The stock has underperformed the Dow (-6.4% to the Dow's -1.7%) and underperformed the S&P 500 (-6.4% to the S&P's -2.0%) during today's trading.
Threshold Pharmaceuticals in Focus: Stock Tumbles 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:59AM CST
Threshold Pharmaceuticals saw a big move last session, as the company’s shares fell nearly 9% on the day
Hot Stock: Threshold Pharmaceuticals, Shares Drop 9.6% (THLD)
Comtex SmarTrend(R) - Mon Jan 27, 11:43AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 9.6% to $4.88 on 1.1x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 604,000 shares, vs. average volume of 555,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's -0.4%) and underperformed the S&P 500 (-9.6% to the S&P's -0.8%) during today's trading.
12.6% Return Seen to Date on SmarTrend Threshold Pharmaceuticals Call (THLD)
Comtex SmarTrend(R) - Thu Jan 23, 10:00AM CST
SmarTrend identified an Uptrend for Threshold Pharmaceuticals (NASDAQ:THLD) on November 27th, 2013 at $4.80. In approximately 2 months, Threshold Pharmaceuticals has returned 12.62% as of today's recent price of $5.40.
2 Biotech Stocks Under $10 to Watch
at The Street - Fri Jan 17, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
How Researchers Are Waging War on the Most Lethal Type of Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 11, 11:31AM CST
Let's face it: The prospect of fighting cancer is scary regardless of what cancer type you're diagnosed with. However, select cancers are certainly more lethal than others. Last year, when we examined the 12 most-diagnosed cancer types, we noted...
Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.
Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma
Marketwire - Mon Dec 30, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company's pivotal Phase 3 trial of TH-302, its investigational hypoxia-targeted drug. The enrollment achievement triggers a milestone payment of $12.5 million USD from Merck KGaA, Darmstadt, Germany. Threshold has a global license and co-development agreement with Merck for TH-302, which includes an option for Threshold to co-commercialize in the U.S.
Threshold Pharmaceuticals Reports TH-302 Data at the 55th Annual Meeting of the American Society of Hematology (ASH)
Marketwire - Sat Dec 07, 9:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that clinical data from two early-stage trials of TH-302, its investigational hypoxia-targeted drug, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place December 7 - 10, 2013, New Orleans, LA.
Threshold Pharmaceuticals Announces Presentation and Webcast at the UBS Global Healthcare Conference
Marketwire - 45 mins ago
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the UBS Global Healthcare Conference on May 20, 2014, at 12:30 p.m. ET.
Threshold CEO Named as Finalist for European Inventor Award
Marketwire - Wed May 07, 5:07AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Harold E. "Barry" Selick, Ph.D., Chief Executive Officer of Threshold and Cary L. Queen, Ph.D., President of Galaxy Biotech, have been jointly named as finalists for the European Inventor Award 2014 in the "Non-European Countries" category. Their nomination is in recognition of their work while at Protein Design Labs, Inc. ("PDL"
in inventing the humanized monoclonal antibody technology that is embodied in numerous therapeutics such as Avastin(R) and Herceptin(R), as well as Zenapax(R), which was the first humanized antibody therapeutic that was approved as a drug by the U.S. Food & Drug Administration (FDA) and which was PDL's first product. Dr. Queen, who led the antibody humanization program, was the co-founder and head of research at PDL while Dr. Selick was a staff scientist working with him at the time. The final award ceremony at which the winners in each of 5 different categories will be announced will take place in Berlin, Germany, on June 17, 2014. Threshold Pharmaceuticals Reports First Quarter 2014 Financial and Operational Results
Marketwire - Thu May 01, 6:01AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the first quarter 2014. Revenue for the first quarter ended March 31, 2014 was $3.7 million. The operating loss for the first quarter ended March 31, 2014 was $8.6 million. The net loss for the first quarter ended March 31, 2014 was $7.1 million, which included the operating loss of $8.6 million and non-cash income of $1.5 million related to the changes in fair value of the Company's outstanding and exercised warrants and was classified as other income (expense). As of March 31, 2014, Threshold had $86.4 million in cash, cash equivalents and marketable securities, with no debt outstanding.
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany Initiates Phase 1 Dose Escalation Study of TH-302 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane(R)) in Pancreatic Cancer
Marketwire - Thu Mar 27, 6:00AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has initiated a Phase 1 dose escalation study assessing the safety, tolerability and anti-tumor activity of the investigational hypoxia-targeted drug TH-302 in combination with gemcitabine and nab-paclitaxel (Abraxane(R)) in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Investors look to Lighten Up on Shares of Threshold Pharmaceuticals, Shares Down 9.4% (THLD)
Comtex SmarTrend(R) - Mon Mar 24, 10:42AM CDT
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 9.4% to $4.51 on 1.3x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 691,000 shares, vs. average volume of 526,000 shares per day. The stock has underperformed the Dow (-9.4% to the Dow's -0.3%) and underperformed the S&P 500 (-9.4% to the S&P's -0.7%) during today's trading.
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
Marketwire - Thu Mar 06, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, the Company's investigational hypoxia-targeted drug, which is currently being evaluated in two pivotal Phase 3 clinical trials, one in patients with advanced soft tissue sarcoma and the other in patients with advanced pancreatic cancer. Revenue for the fourth quarter and year ended December 31, 2013 was $3.2 million and $12.5 million, respectively. Net loss for the fourth quarter ended December 31, 2013 was $7.6 million, which included the operating loss of $7.8 million and non-cash income of $0.2 million related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense). Net loss for the year ended December 31, 2013 was $28.4 million, which included the operating loss of $26.0 million and non-cash expense of $2.3 million related to changes in the fair value of the Company's outstanding and exercised warrants. As of December 31, 2013, Threshold had $82.0 million in cash, cash equivalents and marketable securities, with no debt outstanding. Subsequent to December 31, 2013, Threshold received a $12.5 million milestone payment, which was earned during the fourth quarter of 2013, under its global license and co-development agreement with Merck KGaA, Darmstadt, Germany. The agreement includes an option for Threshold to co-commercialize TH-302 in the U.S.
5 States Where Pancreatic Cancer Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 11:15AM CST
There is no making light of the fact that cancer is a terrible disease, claiming more lives in the U.S. each year save for heart disease. What's even scarier is that cancer prevalence is rising in the U.S., whereas a number of other leading causes of...
3 Biotech Companies That Could Be the Next Intercept or InterMune
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 2:43PM CST
Nearly every industry has witnessed a huge rebound since the market bottomed out in March 2009, but few have delivered as strong a gain since 2012 as the biotech sector. Simply put, biotech stocks are on fire. Venture capital is pouring into the...
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences
Marketwire - Thu Feb 20, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences:
Stock to Watch: Threshold Pharmaceuticals Down 6.4% (THLD)
Comtex SmarTrend(R) - Mon Feb 03, 12:46PM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 6.4% to $4.57 on 1.4x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 828,000 shares, vs. average volume of 587,000 shares per day. The stock has underperformed the Dow (-6.4% to the Dow's -1.7%) and underperformed the S&P 500 (-6.4% to the S&P's -2.0%) during today's trading.
Threshold Pharmaceuticals in Focus: Stock Tumbles 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:59AM CST
Threshold Pharmaceuticals saw a big move last session, as the company’s shares fell nearly 9% on the day
Hot Stock: Threshold Pharmaceuticals, Shares Drop 9.6% (THLD)
Comtex SmarTrend(R) - Mon Jan 27, 11:43AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 9.6% to $4.88 on 1.1x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 604,000 shares, vs. average volume of 555,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's -0.4%) and underperformed the S&P 500 (-9.6% to the S&P's -0.8%) during today's trading.
12.6% Return Seen to Date on SmarTrend Threshold Pharmaceuticals Call (THLD)
Comtex SmarTrend(R) - Thu Jan 23, 10:00AM CST
SmarTrend identified an Uptrend for Threshold Pharmaceuticals (NASDAQ:THLD) on November 27th, 2013 at $4.80. In approximately 2 months, Threshold Pharmaceuticals has returned 12.62% as of today's recent price of $5.40.
2 Biotech Stocks Under $10 to Watch
at The Street - Fri Jan 17, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
How Researchers Are Waging War on the Most Lethal Type of Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 11, 11:31AM CST
Let's face it: The prospect of fighting cancer is scary regardless of what cancer type you're diagnosed with. However, select cancers are certainly more lethal than others. Last year, when we examined the 12 most-diagnosed cancer types, we noted...
Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.
Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma
Marketwire - Mon Dec 30, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company's pivotal Phase 3 trial of TH-302, its investigational hypoxia-targeted drug. The enrollment achievement triggers a milestone payment of $12.5 million USD from Merck KGaA, Darmstadt, Germany. Threshold has a global license and co-development agreement with Merck for TH-302, which includes an option for Threshold to co-commercialize in the U.S.
Threshold Pharmaceuticals Reports TH-302 Data at the 55th Annual Meeting of the American Society of Hematology (ASH)
Marketwire - Sat Dec 07, 9:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that clinical data from two early-stage trials of TH-302, its investigational hypoxia-targeted drug, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place December 7 - 10, 2013, New Orleans, LA.
